Skip to content
Recall Observatory FDA recall evidence

Exact FDA event identifier

Event 97935

13 recalled-product records grouped only because every row carries this exact official event ID.

Open FDA event record

Event summary

Timeline bucket
October 31, 2025
Product types
Drug
Classifications
Class II
Statuses
Ongoing
Recalling firm wording
Blossom Pharmaceuticals

Dossier provenance

Source snapshots represented here

  • openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Complete imported group

Every recalled product in this event

13 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 13

Lanashield Skin Barrier, 4 oz. (113 g), Manfuactured for: Dynarex Corporation, 10 Gleshaw Street, Orangeburg, NY 10962 USA, Made in India, UPC 616784126319.

D-0201-2026
Recall number
D-0201-2026
Initiated
October 31, 2025
Classification
Class II
Status
Ongoing
Recalling firm
Blossom Pharmaceuticals
Quantity
9600 containers

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
cGMP deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP deviations

Code information

Lot #: A162301, Exp. Date 9/26; A162401, Exp. Date 4/27 & A162202, Exp. Date 11/25.

Distribution pattern

USA Nationwide

drug · product 2 of 13

Dynashield Skin Protectant, Net Wt. 16 oz (453.6 g), Manufactured for: Dyrnarex Corporation, 10 Glenshaw Street, Orangeburg, NY 10962, USA, Made in India, NDC 67777-407-04.

D-0202-2026
Recall number
D-0202-2026
Initiated
October 31, 2025
Classification
Class II
Status
Ongoing
Recalling firm
Blossom Pharmaceuticals
Quantity
1560 containers

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
cGMP deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP deviations

Code information

Lot #: A092334, Exp. Date 6/26 & A092421, Exp. Date 7/27

Distribution pattern

USA Nationwide

drug · product 3 of 13

Wecare Enema, 4.5 Fl Oz/133mL, Manufactured for: Dynarex Corporation, 11 Dynarex Corporation, MIddletown, NY 10941 USA, Made in India, NDC 67777-402-01.

D-0203-2026
Recall number
D-0203-2026
Initiated
October 31, 2025
Classification
Class II
Status
Ongoing
Recalling firm
Blossom Pharmaceuticals
Quantity
18912 containers

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
cGMP deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP deviations

Code information

Lot #: A022310, Exp. Date 2/26; A022335, Exp. Date 10/26; A022406, Exp Date 12/27 & A022505, Exp Date 12/27

Distribution pattern

USA Nationwide

drug · product 4 of 13

Dynagel, Moisturizing Wound Hydrogel, Net Wt. 3oz (84.7 g), Manufactured for: Dynarex Corporation, 16 Glenshaw Street, Orangeburg, NY 10962, UPC 61784128016.

D-0204-2026
Recall number
D-0204-2026
Initiated
October 31, 2025
Classification
Class II
Status
Ongoing
Recalling firm
Blossom Pharmaceuticals
Quantity
8184 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
cGMP deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP deviations

Code information

Lot #: A322301, Exp. Date 7/26 & A322302, Exp. Date 8/26

Distribution pattern

USA Nationwide

drug · product 5 of 13

WeCare, Zinc Oxide Ointment, Net Wt. 15 oz/425 g, Manuactured for: Dynarex Corporation, 11 Dynarex Drive, Middletown, NY 10941, Made in India, NDC 67777-223-05.

D-0205-2026
Recall number
D-0205-2026
Initiated
October 31, 2025
Classification
Class II
Status
Ongoing
Recalling firm
Blossom Pharmaceuticals
Quantity
2592 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
cGMP deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP deviations

Code information

Lot #: A062434, Exp. Date 6/27 & A062449, Exp. Date 7/27

Distribution pattern

USA Nationwide

drug · product 6 of 13

Nivagen Pharmaceuticals, Zinc Oxide Ointment USP, Zinc Oxide 20% Skin Protectant, Net Wt. 15 oz (425g), Made in India, Manufactured for: Nivagen Pharmaceuticals, Inc., Sacramento, CA 95827, USA, NDC 75834-170-15.

D-0206-2026
Recall number
D-0206-2026
Initiated
October 31, 2025
Classification
Class II
Status
Ongoing
Recalling firm
Blossom Pharmaceuticals
Quantity
912 containers

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
cGMP deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP deviations

Code information

Lot #: A352318

Distribution pattern

USA Nationwide

drug · product 7 of 13

Dynashield, 4 oz cream (113 g), Manufactured for: Dynarex Corporation, 10 Glenshaw Street, Orangeburg, NY 10852, USA, Made in India, NDC 67777-407-03.

D-0207-2026
Recall number
D-0207-2026
Initiated
October 31, 2025
Classification
Class II
Status
Ongoing
Recalling firm
Blossom Pharmaceuticals
Quantity
7944 containers

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
cGMP deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP deviations

Code information

Lot #: A092421, Exp. Date 7/27, A092340, Exp. Date 10/26 & A092346, Exp. Date 11/26.

Distribution pattern

USA Nationwide

drug · product 8 of 13

Nivagen, Zinc Oxide Ointment, Net Wt. 1 oz. (28.4g), Nivagen Pharmaceuticals, Inc., Sacramento, CA 95827, USA Made in India, NDC 75834-170-01.

D-0208-2026
Recall number
D-0208-2026
Initiated
October 31, 2025
Classification
Class II
Status
Ongoing
Recalling firm
Blossom Pharmaceuticals
Quantity
13536 containers

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
cGMP deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP deviations

Code information

Lot #: A352405

Distribution pattern

USA Nationwide

drug · product 9 of 13

Nivagen, Zinc Oxide Ointment USP, Zinc Oxide 20 %, Net Wt. 1 oz. (28.4g), Nivagen Pharmaceuticals, Inc., Sacramento, CA 95827, USA, Made in India, NDC 75834-170-02.

D-0209-2026
Recall number
D-0209-2026
Initiated
October 31, 2025
Classification
Class II
Status
Ongoing
Recalling firm
Blossom Pharmaceuticals
Quantity
7920 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
cGMP deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP deviations

Code information

Lot #: A352505

Distribution pattern

USA Nationwide

drug · product 10 of 13

Globe Clotrimazole Cream, USP, 1 %, Net Wt. 1 oz (28.4g), Distributed by: Trifecta Pharmaceuticals USA, 101 NE Third Avenue, Suite 1500, Ft. Lauderdale, FL 33301 USA, Made in India, NDC 69396-087-01.

D-0210-2026
Recall number
D-0210-2026
Initiated
October 31, 2025
Classification
Class II
Status
Ongoing
Recalling firm
Blossom Pharmaceuticals
Quantity
12150 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
cGMP deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP deviations

Code information

Lot #: A472408

Distribution pattern

USA Nationwide

drug · product 11 of 13

Globe Clotrimazole Cream USP, 1 % Antifungal Cream, Net Wt., 5 oz. (142 g, Distributed by: Trifecta Pharmaceuticals USA, 101 NE Third Avenue, Suite 1500, Ft. Lauderdale, FL 33301, USA, NDC 69396-087-55.

D-0211-2026
Recall number
D-0211-2026
Initiated
October 31, 2025
Classification
Class II
Status
Ongoing
Recalling firm
Blossom Pharmaceuticals
Quantity
14700 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
cGMP deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP deviations

Code information

Lot #: A472418

Distribution pattern

USA Nationwide

drug · product 12 of 13

Globe Zinc Oxide Ointment USP Zinc Oxide 20% Skin Protectant, Net Wt. 2 oz (56.7 g), Distributed by: Trifecta Pharmaceuticals USA 101 NE, Third Avenue, Suite 1500, Ft. Lauderdale, FL 33301, NDC 69396-086-02.

D-0212-2026
Recall number
D-0212-2026
Initiated
October 31, 2025
Classification
Class II
Status
Ongoing
Recalling firm
Blossom Pharmaceuticals
Quantity
33000 containers

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
cGMP deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP deviations

Code information

Lot #: A502404, Exp. Date 2/27; A502405, Exp. Date 2/27; AS02502, Exp. Date 2/28.

Distribution pattern

USA Nationwide

drug · product 13 of 13

Wecare Calasoothe, Net wt. 4 oz (113 g), Manufactured for: Dynarex Corporation, 10 Glenshaw Street, Orangeburg, NY 10962, NDC 67777-234-04.

D-0213-2026
Recall number
D-0213-2026
Initiated
October 31, 2025
Classification
Class II
Status
Ongoing
Recalling firm
Blossom Pharmaceuticals
Quantity
2400 containers

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0
cGMP deviations

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP deviations

Code information

Lot #: A482305

Distribution pattern

USA Nationwide